BackProShares Trust - ProShares Ultra Nasdaq Biotechnology 2X Shares Overview

ProShares Trust - ProShares Ultra Nasdaq Biotechnology 2X Shares Receivables

ProShares Trust - ProShares Ultra Nasdaq Biotechnology 2X Shares's receivables is $770K.

Get informed when a big investor buys or sells

+ Follow
Receivables
$769000.00
↓ 97.08% YoYΔ $-25.54M vs prior year quarter

Peer average

Loading

ProShares Trust - ProShares Ultra Nasdaq Biotechnology 2X Shares Receivables History

Loading

ProShares Trust - ProShares Ultra Nasdaq Biotechnology 2X Shares vs. peers: Receivables Comparison

Loading

ProShares Trust - ProShares Ultra Nasdaq Biotechnology 2X Shares Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ProShares Trust - ProShares Ultra Nasdaq Biotechnology 2X Shares (BIB) FAQ

As of the most recent data (December 2025), BIB shows a receivables of $770K. That compares with $26M in the prior-year period — down 97.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BIB's receivables is now $770K (was $26M) — a 97.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether ProShares Trust - ProShares Ultra Nasdaq Biotechnology 2X Shares is outperforming or lagging.

Tracking BIB's receivables over time shows whether ProShares Trust - ProShares Ultra Nasdaq Biotechnology 2X Shares is scaling, shrinking, or reshaping that part of the business. The current reading is $770K That compares with $26M in the prior-year period — down 97.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has ProShares Trust - ProShares Ultra Nasdaq Biotechnology 2X Shares's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $770K) with ownership activity and broader fundamentals.